Katie Flaherty
University of Nottingham
20 Papers
52 Citations
Katie Flaherty is an academic researcher from University of Nottingham. The author has contributed to research in topics: Cilostazol & Isosorbide mononitrate. The author has an hindex of 8, co-authored 18 publications. Previous affiliations of Katie Flaherty include Nottingham City Hospital.
Chat about Author
Papers
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial
Nikola Sprigg,Nikola Sprigg,Katie Flaherty,Jason P. Appleton,Rustam Al-Shahi Salman,Dániel Bereczki,Maia Beridze,Hanne Christensen,Alfonso Ciccone,Ronan Collins,Anna Członkowska,Robert A. Dineen,Lelia Duley,Juan José Egea-Guerrero,Timothy J. England,Kailash Krishnan,Kailash Krishnan,Ann Charlotte Laska,Zhe Kang Law,Zhe Kang Law,Zhe Kang Law,Şerefnur Öztürk,Stuart J. Pocock,Ian Roberts,Thompson G. Robinson,Christine Roffe,David J. Seiffge,Polly Scutt,Jegan Thanabalan,David J. Werring,David K. Whynes,Philip M.W. Bath,Philip M.W. Bath +32 more
TL;DR: The tranexamic acid can prevent death due to bleeding after trauma and postpartum haemorrhage in adults with stroke due to intracerebral haemoryrhage as mentioned in this paper.
392
Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination
Gordon W. Blair,Jason P. Appleton,Zhe Kang Law,Zhe Kang Law,Fergus N. Doubal,Katie Flaherty,Richard Dooley,Kirsten Shuler,Carla Richardson,Iona Hamilton,Yulu Shi,Michael S. Stringer,Julia Boyd,Michael J. Thrippleton,Nikola Sprigg,Philip M.W. Bath,Joanna M. Wardlaw +16 more
TL;DR: The LACI-1 trial as mentioned in this paper evaluated the tolerability, safety, and efficacy, by dose, of isosorbide mononitrate and cilostazol, alone and in combination, in patients with ischemic lacunar stroke.
Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT
Philip M.W. Bath,Lisa J Woodhouse,Jason P. Appleton,Jason P. Appleton,Maia Beridze,Hanne Christensen,Robert A. Dineen,Katie Flaherty,Lelia Duley,Timothy J. England,Diane Havard,Stan Heptinstall,Marilyn James,Chibeka Kasonde,Kailash Krishnan,Kailash Krishnan,Hugh S. Markus,Alan A Montgomery,Stuart J. Pocock,Marc Randall,Annamarei Ranta,Thompson G. Robinson,Polly Scutt,Graham Venables,Nikola Sprigg,Nikola Sprigg +25 more
TL;DR: The use of three antiplatelet agents is associated with increased bleeding without any significant reduction in recurrence of stroke or TIA, and the trial was stopped early, thereby reducing its statistical power.
15
Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack
Philip M.W. Bath,Philip M.W. Bath,Jane May,Katie Flaherty,Lisa J Woodhouse,Natalia Dovlatova,Susan C. Fox,Timothy J. England,Kailash Krishnan,Kailash Krishnan,Thompson G. Robinson,Nikola Sprigg,Nikola Sprigg,Stan Heptinstall,Tardis Trial Investigators +14 more
TL;DR: Aspirin and clopidogrel suppress stimulated platelet P-selectin, although one-quarter of patients on clopIDogrel have high on-treatment platelet reactivity, and platelet function testing may be performed remotely in the context of a large multicentre trial.
Does tranexamic acid lead to changes in MRI measures of brain tissue health in patients with spontaneous intracerebral haemorrhage? Protocol for a MRI substudy nested within the double-blind randomised controlled TICH-2 trial
Robert A. Dineen,Stefan Pszczolkowski,Katie Flaherty,Zhe Kang Law,Paul S. Morgan,Ian Roberts,David J. Werring,Rustam Al-Shahi Salman,Timothy J. England,Philip M.W. Bath,Nikola Sprigg +10 more
TL;DR: The TICH-2 MRI substudy will test whether TXA increases the incidence of new DWI-defined ischaemic lesions or reduces perihaematomal oedema or final ICH lesion volume in the context of SICH.
10